Abstract
Introduction: The variants in the zinc finger (ZF) domains 1–3 in WT1 are one of the major causes of 46,XY disorders of sex development (DSD). Recently, variants in the fourth ZF (ZF4 variants) were reported to cause 46,XX DSD. However, all the 9 patients reported were de novo, and no familial cases were identified. Case Presentation and Results: The proband (16-year-old social female) had a 46,XX karyotype with dysplastic testes and moderate virilization in genitalia. A ZF4 variant, p.Arg495Gln, in WT1 was identified in the proband, her brother, and mother. The mother did not show any virilization with normal fertility, and the 46,XY brother developed normal puberty. Conclusion: The phenotypic variations due to the ZF4 variant are extremely broad in 46,XX cases.
Journal Section:
Short Report
References
1.
Achermann
JC
, Ito
M
, Ito
M
, Hindmarsh
PC
, Jameson
JL
. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans
. Nat Genet
. 1999
;22
(2
):125
–6
. https://doi.org/10.1038/9629.2.
Baetens
D
, Stoop
H
, Peelman
F
, Todeschini
AL
, Rosseel
T
, Coppieters
F
, . NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development
. Genet Med
. 2017
;19
(4
):367
–76
.3.
Bandiera
R
, Sacco
S
, Vidal
VPI
, Chaboissier
MC
, Schedl
A
. Steroidogenic organ development and homeostasis: a WT1-centric view
. Mol Cell Endocrinol
. 2015
;408
:145
–55
.4.
Barbaux
S
, Niaudet
P
, Gubler
MC
, Grunfeld
JP
, Jaubert
F
, Kuttenn
F
, . Donor splice-site mutations in WT1 are responsible for Frasier syndrome
. Nat Genet
. 1997
;17
(4
):467
–70
.5.
Bashamboo
A
, Donohoue
PA
, Vilain
E
, Rojo
S
, Calvel
P
, Seneviratne
SN
, . A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development
. Hum Mol Genet
. 2016
;25
(23
):5286
.6.
Bullejos
M
, Koopman
P
. Delayed Sry and Sox9 expression in developing mouse gonads underlies B6-Y(DOM) sex reversal
. Dev Biol
. 2005
;278
(2
):473
–81
.7.
Call
KM
, Glaser
T
, Ito
CY
, Buckler
AJ
, Pelletier
J
, Haber
DA
, . Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus
. Cell
. 1990
;60
(3
):509
–20
.8.
Eozenou
C
, Gonen
N
, Touzon
MS
, Jorgensen
A
, Yatsenko
SA
, Fusee
L
, . Testis formation in XX individuals resulting from novel pathogenic variants in Wilms’ tumor 1 (WT1) gene
. Proc Natl Acad Sci U S A
. 2020
;117
(24
):13680
–8
.9.
Ferrari
MTM
, da Silva
TE
, Watanabe
A
, Gomes
NL
, Batista
RL
, Nishi
MY
, . WT1 pathogenic variants are associated with a broad spectrum of differences in sex development phenotypes and heterogeneous progression of renal disease
. Sex Dev
. 2022
;16
(1
):46
–54
.10.
Gomes
NL
, de Paula
LCP
, Silva
JM
, Silva
TE
, Lerario
AM
, Nishi
MY
, . A 46,XX testicular disorder of sex development caused by a Wilms’ tumour Factor-1 (WT1) pathogenic variant
. Clin Genet
. 2019
;95
(1
):172
–6
.11.
Hiramatsu
R
, Matoba
S
, Kanai-Azuma
M
, Tsunekawa
N
, Katoh-Fukui
Y
, Kurohmaru
M
, . A critical time window of Sry action in gonadal sex determination in mice
. Development
. 2009
;136
(1
):129
–38
.12.
Igarashi
M
, Takasawa
K
, Hakoda
A
, Kanno
J
, Takada
S
, Miyado
M
, . Identical NR5A1 missense mutations in two unrelated 46,XX individuals with testicular tissues
. Hum Mutat
. 2017
;38
(1
):39
–42
.13.
Kreidberg
JA
, Sariola
H
, Loring
JM
, Maeda
M
, Pelletier
J
, Housman
D
, . WT-1 is required for early kidney development
. Cell
. 1993
;74
(4
):679
–91
.14.
Mori
T
, Hosomichi
K
, Chiga
M
, Mandai
S
, Nakaoka
H
, Sohara
E
, . Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel
. Clin Exp Nephrol
. 2017
;21
(1
):63
–75
.15.
Morohashi
K
, Honda
S
, Inomata
Y
, Handa
H
, Omura
T
. A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s
. J Biol Chem
. 1992
;267
(25
):17913
–9
.16.
Pelletier
J
, Ono
M
, Harley
VR
, Bruening
W
, Kashtan
CE
, Mauer
SM
, . Disorders of sex development: new genes, new concepts germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
. Nat Rev Endocrinol Cell
. 1991a
;967
:79437
–91447
.17.
Ono
M
, Harley
VR
. Disorders of sex development: new genes, new concepts
. Nat Rev Endocrinology
. 2013
;9
(2
):79
–91
. .
[PubMed]
.18.
Pelletier
J
, Bruening
W
, Li
FP
, Haber
DA
, Glaser
T
, Housman
DE
. WT1 mutations contribute to abnormal genital system development and hereditary Wilms’ tumour
. Nature
. 1991b
;353
(6343
):431
–4
.19.
Sirokha
D
, Gorodna
O
, Vitrenko
Y
, Zelinska
N
, Ploski
R
, Nef
S
, . A novel WT1 mutation identified in a 46,XX testicular/ovotesticular DSD patient results in the retention of intron 9
. Biology
. 2021
;10
(12
):1248
.20.
Suri
M
, Kelehan
P
, O’Neill
D
, Vadeyar
S
, Grant
J
, Ahmed
SF
, . WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations
. Am J Med Genet A
. 2007
;143A
(19
):2312
–20
.21.
Takasawa
K
, Igarashi
M
, Ono
M
, Takemoto
A
, Takada
S
, Yamataka
A
, . Phenotypic variation in 46,XX disorders of sex development due to the NR5A1 p.R92W variant: a sibling case report and literature review
. Sex Dev
. 2017
;11
(5-6
):284
–8
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
